Trial Outcomes & Findings for An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD (NCT NCT04201262)

NCT ID: NCT04201262

Last Updated: 2025-10-14

Results Overview

An On-trial Relapse was defined as a new onset of neurologic symptoms or worsening of existing neurologic symptoms with an objective change (clinical sign) on neurologic examination that persisted for more than 24 hours as confirmed by the treating physician. An adjudicated On-trial Relapse was defined by the protocol and positively adjudicated by the independent relapse adjudication committee.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 58 participants
• Primary outcome timeframe: Baseline up to 2.25 years (end of the Primary Treatment Period)
• Results posted on: 2025-10-14

Participant Flow

This study utilized the placebo group from Study ECU-NMO-301 (NCT01892345) as an external placebo control.

Participant milestones

Measure	Ravulizumab Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) Participants who received eculizumab matching placebo in study ECU-NMO-301.
Primary Treatment Period STARTED	58	47
Primary Treatment Period Received at Least 1 Dose of Study Drug	58	47
Primary Treatment Period COMPLETED	56	44
Primary Treatment Period NOT COMPLETED	2	3
Long-term Extension Period STARTED	56	0
Long-term Extension Period Received at Least 1 Dose of Study Drug	56	0
Long-term Extension Period COMPLETED	55	0
Long-term Extension Period NOT COMPLETED	1	0

Reasons for withdrawal

Measure	Ravulizumab Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) Participants who received eculizumab matching placebo in study ECU-NMO-301.
Primary Treatment Period Adverse Event	1	2
Primary Treatment Period Physician Decision	1	1
Long-term Extension Period Death	1	0

Baseline Characteristics

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Baseline characteristics by cohort

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) n=47 Participants Participants who received eculizumab matching placebo in study ECU-NMO-301.	Total n=105 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	51 Participants n=5 Participants	44 Participants n=7 Participants	95 Participants n=5 Participants
Age, Categorical >=65 years	7 Participants n=5 Participants	3 Participants n=7 Participants	10 Participants n=5 Participants
Sex: Female, Male Female	52 Participants n=5 Participants	42 Participants n=7 Participants	94 Participants n=5 Participants
Sex: Female, Male Male	6 Participants n=5 Participants	5 Participants n=7 Participants	11 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	9 Participants n=5 Participants	3 Participants n=7 Participants	12 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	45 Participants n=5 Participants	41 Participants n=7 Participants	86 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	4 Participants n=5 Participants	3 Participants n=7 Participants	7 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Asian	21 Participants n=5 Participants	15 Participants n=7 Participants	36 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	6 Participants n=5 Participants	8 Participants n=7 Participants	14 Participants n=5 Participants
Race (NIH/OMB) White	29 Participants n=5 Participants	24 Participants n=7 Participants	53 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	2 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants

PRIMARY outcome

Timeframe: Baseline up to 2.25 years (end of the Primary Treatment Period)

Population: The full analysis set (FAS) included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

An On-trial Relapse was defined as a new onset of neurologic symptoms or worsening of existing neurologic symptoms with an objective change (clinical sign) on neurologic examination that persisted for more than 24 hours as confirmed by the treating physician. An adjudicated On-trial Relapse was defined by the protocol and positively adjudicated by the independent relapse adjudication committee.

Outcome measures

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) n=47 Participants Participants who received eculizumab matching placebo in study ECU-NMO-301.
Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period	0 Participants	20 Participants

SECONDARY outcome

Timeframe: Baseline up to 2.25 years (end of the Primary Treatment Period)

Population: The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

The adjudicated On-trial ARR was computed as the total number of relapses divided by the total number of participant years in the study period. A central independent committee was used to adjudicate all On-trial Relapses as determined by the treating physician. Results reported as adjusted adjudicated On-trial ARR based on a Poisson regression centered on the mean historical ARR in the 24 months prior to screening.

Outcome measures

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) n=47 Participants Participants who received eculizumab matching placebo in study ECU-NMO-301.
Adjudicated On-trial Annualized Relapse Rate (ARR) in the Primary Treatment Period	0.000 relapses/year on study Since there were no relapses, data could not be estimated.	0.350 relapses/year on study Interval 0.199 to 0.616

SECONDARY outcome

Timeframe: Baseline up to 2.25 years (end of the Primary Treatment Period)

Population: The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

The HAI is a rating scale developed to assess mobility by evaluating the time and degree of assistance required to walk 25 feet. The scale ranges from 0 to 9, with 0 being the best score (asymptomatic; fully ambulatory with no assistance) and 9 being the worst (restricted to wheelchair; unable to transfer self independently). Clinically important change is conditional on the baseline value: worsening if the baseline HAI is 0 and at least 2 points increase or if the baseline HAI is >0 and at least 1 point increase; improvement if the baseline value is at least 2 and at least 1 point decrease; and stable if baseline is 0 or 1 and a 0- or 1-point increase or decrease or baseline is at least 2 and not change.

Outcome measures

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) n=47 Participants Participants who received eculizumab matching placebo in study ECU-NMO-301.
Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period Clinical Improvement	4 Participants	4 Participants
Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period Stable	52 Participants	32 Participants
Number of Participants With Clinically Important Change From Baseline in Hauser Ambulation Index (HAI) Score at the End of Primary Treatment Period Clinical Worsening	2 Participants	11 Participants

SECONDARY outcome

Timeframe: Baseline, up to 2.25 years (end of the Primary Treatment Period)

Population: The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

The EQ-5D is a generic, standardized, self-administered instrument that provides a simple, descriptive profile and a single index value for health status. It consists of 2 parts; the EQ-5D descriptive system and the EQ-5D visual analogue scale (VAS). The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score that ranges from less than 0 to 1, with higher scores representing a better health status.

Outcome measures

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) n=47 Participants Participants who received eculizumab matching placebo in study ECU-NMO-301.
Change From Baseline in European Quality of Life Health 5-dimension Questionnaire (EQ-5D) Index Score at the End of Primary Treatment Period	0.005 units on a scale Standard Deviation 0.1522	-0.043 units on a scale Standard Deviation 0.2115

SECONDARY outcome

Timeframe: Baseline, up to 2.25 years (end of the Primary Treatment Period)

Population: The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

The EQ-5D is a generic, standardized, self-administered instrument that provides a simple, descriptive profile and a single index value for health status. It consists of 2 parts; the EQ-5D descriptive system and the EQ-5D visual analogue scale (VAS). The EQ-5D VAS is an overall health state scale where the participant selects a number between 0 to 100 to describe the condition of their health, with 100 being 'The best health state you can imagine' and 0 being 'The worst health state you can imagine'. An increase in score indicates improvement.

Outcome measures

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) n=47 Participants Participants who received eculizumab matching placebo in study ECU-NMO-301.
Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at the End of Primary Treatment Period	2.6 units on a scale Standard Deviation 14.07	0.6 units on a scale Standard Deviation 16.39

SECONDARY outcome

Timeframe: Baseline up to 2.25 years (end of the Primary Treatment Period)

Population: The FAS included all participants who had received at least 1 dose of study drug (ravulizumab or placebo).

Disease-related disability was measured by the EDSS. The EDSS is an ordinal clinical rating scale that ranges from 0 (normal neurologic examination) to 10 (death) in half-point increments. Clinically important worsening was defined as an increase in EDSS score conditional on the baseline value: If the baseline EDSS was 0 and at least 2-point increase; if the baseline is 1 to 5, and at least 1-point increase; if the baseline is > 5 and at least 0.5 increase.

Outcome measures

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) n=47 Participants Participants who received eculizumab matching placebo in study ECU-NMO-301.
Number of Participants With Clinically Important Worsening From Baseline in Expanded Disability Status Scale (EDSS) Score at the End of Primary Treatment Period No clinically important worsening	52 Participants	36 Participants
Number of Participants With Clinically Important Worsening From Baseline in Expanded Disability Status Scale (EDSS) Score at the End of Primary Treatment Period Clinically important worsening	6 Participants	11 Participants

SECONDARY outcome

Timeframe: Baseline up to 2.25 years (end of the Primary Treatment Period)

Population: The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo).

An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. TEAEs were AEs with a start date on or after the date of the first dose of study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Outcome measures

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) n=47 Participants Participants who received eculizumab matching placebo in study ECU-NMO-301.
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Study Drug Discontinuation in the Primary Treatment Period Any TEAEs	53 Participants	45 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Study Drug Discontinuation in the Primary Treatment Period TESAEs	8 Participants	26 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Study Drug Discontinuation in the Primary Treatment Period TEAEs Leading to Study Drug Discontinuation	1 Participants	2 Participants

SECONDARY outcome

Timeframe: Predose and end of infusion (EOI) at Week 26

Population: Pharmacokinetics/pharmacodynamics (PK/PD) analysis set included participants who received at least 1 dose of study drug and who had at least 1 evaluable PK or PD result. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.

Outcome measures

Measure	Ravulizumab n=56 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) Participants who received eculizumab matching placebo in study ECU-NMO-301.
Serum Ravulizumab Concentration Week 26: Predose	760.3 micrograms (µg)/milliliter (mL) Standard Deviation 202.75	—
Serum Ravulizumab Concentration Week 26: EOI	1836.4 micrograms (µg)/milliliter (mL) Standard Deviation 355.39	—

SECONDARY outcome

Timeframe: Baseline, Week 26 (Predose and EOI)

Population: The PK/PD analysis set included participants who received at least 1 dose of study drug and who had at least 1 evaluable PK or PD result. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed' = participants evaluable at specified timepoint.

Outcome measures

Measure	Ravulizumab n=55 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) Participants who received eculizumab matching placebo in study ECU-NMO-301.
Change From Baseline in Serum Free C5 Concentration at Week 26 Change at Week 26: Predose	-119.02 µg/mL Standard Deviation 42.857	—
Change From Baseline in Serum Free C5 Concentration at Week 26 Change at Week 26: EOI	-119.32 µg/mL Standard Deviation 42.512	—

SECONDARY outcome

Timeframe: Baseline, Weeks 26, 50, 82, and 106

Population: The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Here, 'Number analyzed' = participants evaluable at specified timepoint.

Outcome measures

Measure	Ravulizumab n=58 Participants Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Placebo (ECU-NMO-301) Participants who received eculizumab matching placebo in study ECU-NMO-301.
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Baseline · Positive	5 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Baseline · Negative	53 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Week 26 · Positive	1 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Week 26 · Negative	54 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Week 50 · Positive	0 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Week 50 · Negative	52 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Week 82 · Positive	0 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Week 82 · Negative	15 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Week 106 · Positive	0 Participants	—
Number of Participants With Anti-drug Antibodies (ADAs) During the Primary Treatment Period Week 106 · Negative	1 Participants	—

Adverse Events

Primary Treatment Period: Placebo

Serious events: 26 serious events

Other events: 43 other events

Deaths: 0 deaths

Primary Treatment Period: Ravulizumab

Serious events: 8 serious events

Other events: 53 other events

Deaths: 0 deaths

Long-Term Extension: Ravulizumab

Serious events: 9 serious events

Other events: 49 other events

Deaths: 1 deaths

Serious adverse events

Measure	Primary Treatment Period: Placebo n=47 participants at risk Participants who received eculizumab matching placebo in study ECU-NMO-301.	Primary Treatment Period: Ravulizumab n=58 participants at risk Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Long-Term Extension: Ravulizumab n=56 participants at risk Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive lobular breast carcinoma	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Myelitis transverse	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Blood and lymphatic system disorders Pancytopenia	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Cardiac disorders Myocardial ischaemia	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Abdominal pain	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Pancreatitis	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Hepatobiliary disorders Cholecystitis acute	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Encephalitis meningococcal	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Intervertebral discitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Meningococcal sepsis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Pneumonia	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Bronchitis	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Gastroenteritis viral	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Herpes zoster	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Influenza	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Pneumococcal infection	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Viral upper respiratory tract infection	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Rib fracture	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Muscular weakness	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Neuromyelitis optica spectrum disorder	34.0% 16/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Paraesthesia	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Somnolence	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Syncope	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Suicidal ideation	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Confusional state	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Pleurisy	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Respiratory disorder	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Vascular disorders Orthostatic hypotension	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Cardiac disorders Cardiac failure	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Cardiac disorders Hypertensive heart disease	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Cellulitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Post lumbar puncture syndrome	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Ulna fracture	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Salivary gland neoplasm	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Neuromyelitis optica pseudo relapse	2.1% 1/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Vascular disorders Deep vein thrombosis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Cataract	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.

Other adverse events

Measure	Primary Treatment Period: Placebo n=47 participants at risk Participants who received eculizumab matching placebo in study ECU-NMO-301.	Primary Treatment Period: Ravulizumab n=58 participants at risk Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.	Long-Term Extension: Ravulizumab n=56 participants at risk Participants received a weight-based loading dose of ravulizumab via intravenous (IV) infusion on Day 1, followed by weight-based maintenance doses on Day 15, then once every 8 weeks until the end of primary treatment period (up to 2.25 years). After the primary treatment period, participants continued to receive ravulizumab during the Long-Term Extension Period for up to approximately 2.63 years.
Ear and labyrinth disorders Tinnitus	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Blood and lymphatic system disorders Anaemia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Blood and lymphatic system disorders Iron deficiency anaemia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Blood and lymphatic system disorders Lymphadenopathy	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Blood and lymphatic system disorders Leukopenia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Cardiac disorders Tachycardia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Cardiac disorders Bradycardia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Cardiac disorders Extrasystoles	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Cardiac disorders Pericardial effusion	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Ear and labyrinth disorders Vertigo	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.4% 3/56 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Ear and labyrinth disorders Ear pain	4.3% 2/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Ear and labyrinth disorders Paraesthesia ear	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Ear and labyrinth disorders Eustachian tube dysfunction	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Endocrine disorders Thyroid cyst	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Endocrine disorders Thyroid mass	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Blepharitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Conjunctivitis allergic	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Eye disorder	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Eye pain	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Ocular discomfort	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Ocular hyperaemia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Vision blurred	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Visual impairment	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Cataract	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Conjunctival haemorrhage	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Photophobia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Retinal degeneration	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Constipation	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	6.9% 4/58 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Abdominal distension	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Migraine	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 4 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Vomiting	17.0% 8/47 • Number of events 10 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	6.9% 4/58 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Diarrhoea	12.8% 6/47 • Number of events 14 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	8.9% 5/56 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Gastrooesophageal reflux disease	6.4% 3/47 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 4 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Nausea	25.5% 12/47 • Number of events 17 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.4% 3/56 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Alveolar bone resorption	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Anal incontinence	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Dry mouth	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Dyspepsia	8.5% 4/47 • Number of events 4 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Food poisoning	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Gastric ulcer	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Blood glucose increased	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Periodontal disease	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Stomatitis	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Abdominal pain	4.3% 2/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Abdominal pain upper	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Abdominal tenderness	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Angular cheilitis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Aphthous ulcer	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Colitis microscopic	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Gingival pain	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Intestinal obstruction	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Lip blister	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Lip pain	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Mouth ulceration	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Presbyoesophagus	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Toothache	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Hepatobiliary disorders Hepatic steatosis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Hepatobiliary disorders Cholecystitis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Hepatobiliary disorders Cholelithiasis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Hepatobiliary disorders Hepatic function abnormal	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Immune system disorders Allergy to arthropod bite	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Immune system disorders Seasonal allergy	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations COVID-19	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	24.1% 14/58 • Number of events 15 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	28.6% 16/56 • Number of events 16 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Urinary tract infection	19.1% 9/47 • Number of events 12 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	10.3% 6/58 • Number of events 7 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	10.7% 6/56 • Number of events 14 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Cystitis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	8.6% 5/58 • Number of events 7 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Upper respiratory tract infection	12.8% 6/47 • Number of events 10 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	8.6% 5/58 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	10.7% 6/56 • Number of events 12 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Nasopharyngitis	17.0% 8/47 • Number of events 12 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	7.1% 4/56 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Sinusitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Conjunctivitis	8.5% 4/47 • Number of events 8 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Oral herpes	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	7.1% 4/56 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Periodontitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Bronchitis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Cellulitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Gingivitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Herpes simplex	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Laryngitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Nasal herpes	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Paronychia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Post-acute COVID-19 syndrome	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Rhinitis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Stenotrophomonas infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Alcohol poisoning	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Tinea pedis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Tinea versicolour	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Tooth infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Viral pharyngitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Vulvovaginal candidiasis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Bacterial vaginosis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Body tinea	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Chronic tonsillitis	2.1% 1/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Diarrhoea infectious	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Ear infection	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Gastroenteritis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Influenza	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Lower respiratory tract infection	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Mastitis bacterial	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Nail infection	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Oesophageal candidiasis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Onychomycosis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Oral candidiasis	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Otitis externa	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Pharyngitis	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Pneumonia	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Post procedural infection	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Tooth abscess	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Viral upper respiratory tract infection	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Vulvovaginal mycotic infection	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Cartilage injury	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Concussion	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Joint dislocation	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Ligament sprain	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Limb injury	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Muscle strain	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Post lumbar puncture syndrome	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Rib fracture	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Skin abrasion	4.3% 2/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Tooth fracture	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Chillblains	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Contusion	4.3% 2/47 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Fall	8.5% 4/47 • Number of events 8 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Fibula fracture	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Foot fracture	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Fractured sacrum	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Head injury	2.1% 1/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Injury	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Post procedural contusion	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Procedural complication	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Skin laceration	4.3% 2/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Stress fracture	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Thermal burn	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Thoracic vertebral fracture	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Wound	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Hepatic enzyme increased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Lymphocyte count decreased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Alanine aminotransferase increased	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Aspartate aminotransferase increased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Blood creatinine increased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Haemoglobin decreased	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations SARS-CoV-2 test positive	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Urinary occult blood	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Blood potassium decreased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Blood pressure systolic increased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Bone density decreased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Cortisol decreased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Electrocardiogram abnormal	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Gardnerella test positive	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Neutrophil count decreased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Weight decreased	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Weight increased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations White blood cell count decreased	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Hyperglycaemia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Hypercholesterolaemia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Hypokalaemia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Vitamin D deficiency	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Decreased appetite	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Dehydration	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Folate deficiency	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Hypophosphataemia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Hypoproteinaemia	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Iron deficiency	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Back pain	12.8% 6/47 • Number of events 9 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	12.1% 7/58 • Number of events 8 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Arthralgia	8.5% 4/47 • Number of events 9 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	10.3% 6/58 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Myalgia	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Neck pain	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Pain in extremity	21.3% 10/47 • Number of events 11 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Joint swelling	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Limb discomfort	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Muscle spasms	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Pelvic deformity	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Periarthritis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Rheumatoid arthritis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Flank pain	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Fracture pain	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Muscular weakness	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Osteonecrosis	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Osteopenia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Osteoporosis	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Synovial disorder	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm skin	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Uterine leiomyoma	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Anogenital warts	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal adenoma	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Headache	21.3% 10/47 • Number of events 17 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	25.9% 15/58 • Number of events 25 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	8.9% 5/56 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Dizziness	12.8% 6/47 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	6.9% 4/58 • Number of events 4 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Paraesthesia	6.4% 3/47 • Number of events 4 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Hypoaesthesia	8.5% 4/47 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Memory impairment	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Parosmia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Presyncope	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Sensory disturbance	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Somnolence	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Syncope	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Burning sensation	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Dysgeusia	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Head discomfort	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Mental impairment	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Muscle contractions involuntary	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Muscle spasticity	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Neuralgia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Post herpetic neuralgia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Uhthoff's phenomenon	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Anxiety	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Insomnia	8.5% 4/47 • Number of events 4 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Depressed mood	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Depression	8.5% 4/47 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.4% 3/56 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Post-traumatic stress disorder	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Sleep talking	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Suicidal ideation	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Agitation	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Delusion	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Hallucination	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Obsessive-compulsive disorder	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Persistent depressive disorder	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Sleep disorder	4.3% 2/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Dysuria	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Acute kidney injury	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Haematuria	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Proteinuria	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Strangury	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Cystitis interstitial	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Glycosuria	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Nephrolithiasis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Pollakiuria	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Prerenal failure	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Urethral syndrome	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Urinary incontinence	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Menopausal symptoms	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Vulvovaginal pruritus	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Dysmenorrhoea	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Endometrial hyperplasia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Menstruation irregular	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Cough	12.8% 6/47 • Number of events 8 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.4% 3/56 • Number of events 4 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Dyspnoea	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Epistaxis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Obstructive sleep apnoea syndrome	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Sinus congestion	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Atelectasis	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Dysphonia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Nasal congestion	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Nasal discomfort	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Productive cough	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Respiratory disorder	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Sinus disorder	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Tonsillolith	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Acne	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Purpura	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Alopecia	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Rash	8.5% 4/47 • Number of events 4 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Dermatitis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Dry skin	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Eczema	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Erythema	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Hyperkeratosis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Ingrowing nail	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Pruritus	8.5% 4/47 • Number of events 8 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Psoriasis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Sensitive skin	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Urticaria	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Dermatitis allergic	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Dermatitis contact	4.3% 2/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Hyperhidrosis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Petechiae	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Pityriasis rosea	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Rash maculo-papular	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Skin lesion	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Social circumstances Menopause	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Vascular disorders Hypertension	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Vascular disorders Deep vein thrombosis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Vascular disorders Lymphoedema	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Vascular disorders Flushing	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Vascular disorders Hypotension	4.3% 2/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Vascular disorders Orthostatic hypotension	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Blood and lymphatic system disorders Lymphopenia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Blood and lymphatic system disorders Macrocytosis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Blood and lymphatic system disorders Neutropenia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Cardiac disorders Heart failure with preserved ejection fraction	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Dry eye	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Eyelid ptosis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Eye disorders Photopsia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Abdominal fat apron	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Abdominal pain lower	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Dental caries	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Dysphagia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Faeces soft	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Gastritis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Haematochezia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Hiatus hernia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Pancreatic cyst	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Rectal polyp	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Herpes zoster	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.4% 3/56 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Localised infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Respiratory tract infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Bacterial vulvovaginitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Conjunctivitis viral	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Coronavirus infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Diverticulitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Eye infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Folliculitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Fungal skin infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Hordeolum	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Otitis media	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Pharyngitis streptococcal	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Postoperative wound infection	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Respiratory tract infection viral	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Subcutaneous abscess	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Immunisation reaction	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Animal bite	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Arthropod bite	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Arthropod sting	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Hand fracture	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Procedural headache	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Pulmonary contusion	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Wound complication	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Antinuclear antibody positive	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Blood urea increased	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Culture cervix positive	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Protein urine present	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Red blood cell sedimentation rate increased	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Muscle contracture	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Synovial cyst	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Systemic lupus erythematosus	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Temporomandibular pain and dysfunction syndrome	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Foot deformity	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Plantar fasciitis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign soft tissue neoplasm	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Carpal tunnel syndrome	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Facial paralysis	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Migraine with aura	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Neuromyelitis optica pseudo relapse	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Partial seizures with secondary generalisation	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Nervous system disorders Tremor	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Psychiatric disorders Attention deficit hyperactivity disorder	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Cystitis-like symptom	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Renal and urinary disorders Micturition urgency	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Breast pain	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.6% 2/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Intermenstrual bleeding	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Catarrh	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Cough variant asthma	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Paranasal sinus inflammation	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Pleural thickening	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Androgenetic alopecia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Dyshidrotic eczema	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Skin and subcutaneous tissue disorders Pigmentation disorder	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Metabolism and nutrition disorders Hyperlipidaemia	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Gastrointestinal disorders Anorectal discomfort	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Asthenia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Axillary pain	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Chest discomfort	4.3% 2/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Chest pain	4.3% 2/47 • Number of events 12 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Chills	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Cyst	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Fatigue	10.6% 5/47 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Feeling cold	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Gait disturbance	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Generalised oedema	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Induration	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Influenza like illness	2.1% 1/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Injection site reaction	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Malaise	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Non-cardiac chest pain	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Oedema	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Oedema peripheral	6.4% 3/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Pain	8.5% 4/47 • Number of events 7 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	3.4% 2/58 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Peripheral swelling	4.3% 2/47 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Pyrexia	8.5% 4/47 • Number of events 5 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	8.6% 5/58 • Number of events 6 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Swelling face	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Vaccination site pain	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	5.2% 3/58 • Number of events 3 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
General disorders Vaccination site pruritus	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.7% 1/58 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Enterococcal bacteraemia	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Klebsiella bacteraemia	2.1% 1/47 • Number of events 2 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Infections and infestations Otitis media chronic	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Injury, poisoning and procedural complications Foreign body	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Investigations Blood creatinine decreased	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Musculoskeletal and connective tissue disorders Spinal retrolisthesis	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Dysplastic naevus	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Product Issues Medical device entrapment	0.00% 0/47 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	1.8% 1/56 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Heavy menstrual bleeding	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.
Reproductive system and breast disorders Lactation insufficiency	2.1% 1/47 • Number of events 1 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/58 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.	0.00% 0/56 • Up to approximately 4.9 years. The safety set included all participants who received at least 1 dose of study drug (ravulizumab or placebo). Per pre-specified analysis, data for the placebo arm (study ECU-NMO-301) was specified to be reported for primary analysis results only. Data were collected and are reported for the ravulizumab arm for the primary treatment period and long-term extension period separately.

Additional Information

Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc.

Phone: 855-752-2356

Email: clinicaltrials@alexion.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place